ReviewDrug discovery today2026
Allosteric drugs in biomolecular condensates: ways forward.
Review in Drug discovery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial biology of crowded tumor cells: A new map for designing drug combinations.Current opinion in structural biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Biomacromolecular condensates are membraneless compartments that form through the dynamic assembly of function-related macromolecules to perform specific functions, such as signaling and gene expression. They have crucial roles in disease, fueling significant interest in their therapeutic potential. Efforts largely focus on condensate-modulating drugs, disrupting the crowded, interlinked molecular mesh. Although this is an important aim, such drugs might not be as specific as 'classical' allosteric drugs, and it remains challenging to optimize highly specific allosteric drugs. Condensate-resident proteins are intimately linked to allosteric behavior, making allosteric drugs, which are highly specific, their prioritized targets. This work examines the two classes of allosteric drugs, exploring how biomolecular condensates can be leveraged to advance a new era of condensate-adapted, protein-specific allosteric drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.